Royalty Pharma plc
RPRX
Classement en actions
#895
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Prix de l'action
$60.39
Capitalisation boursière
$26.89B
Changement (1 jour)
-0.93%
Changement (1 an)
63.17%
Pays
US
Échange Royalty Pharma plc (RPRX)
Catégorie
Healthcare
EPS pour Royalty Pharma plc (RPRX)
EPS au June 2026 TTM : $2.41
Selon les derniers rapports financiers et le cours de l'action de Royalty Pharma plc, l’EPS actuel de la société (TTM) est de $2.41. À la fin de 2024, la société avait un EPS de $1.92 une diminution par rapport à celui de 2023, qui était de $2.54.
Historique de l'EPS de Royalty Pharma plc de 2015 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $2.41 | 34.64% |
| 2025 | $1.79 | -6.61% |
| 2024 | $1.92 | -24.41% |
| 2023 | $2.54 | 2,492.43% |
| 2022 | $0.10 | -93.45% |
| 2021 | $1.49 | -42.47% |
| 2020 | $2.60 | -59.54% |
| 2019 | $6.42 | 182.80% |
| 2018 | $2.27 | 13.86% |
| 2017 | $1.99 | 113.83% |
| 2016 | $0.93 | -2.67% |
| 2015 | $0.96 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -78.42% |
US
|
|
| $0.02 | -99.22% |
HK
|
